HK1161141A1 - A beta 1-42 specific monoclonal antibodies with therapeutic properties - Google Patents
A beta 1-42 specific monoclonal antibodies with therapeutic propertiesInfo
- Publication number
- HK1161141A1 HK1161141A1 HK12102086.7A HK12102086A HK1161141A1 HK 1161141 A1 HK1161141 A1 HK 1161141A1 HK 12102086 A HK12102086 A HK 12102086A HK 1161141 A1 HK1161141 A1 HK 1161141A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- beta
- monoclonal antibodies
- specific monoclonal
- therapeutic properties
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05027092 | 2005-12-12 | ||
EP06014729 | 2006-07-14 | ||
EP06020766 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1161141A1 true HK1161141A1 (en) | 2012-08-24 |
Family
ID=37896141
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12102086.7A HK1161141A1 (en) | 2005-12-12 | 2012-02-29 | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
HK15105249.1A HK1204579A1 (en) | 2005-12-12 | 2015-06-02 | A beta 1-42 specific monoclonal antibodies with therapeutic properties a1-42 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105249.1A HK1204579A1 (en) | 2005-12-12 | 2015-06-02 | A beta 1-42 specific monoclonal antibodies with therapeutic properties a1-42 |
Country Status (32)
Country | Link |
---|---|
US (5) | US7772375B2 (he) |
EP (3) | EP2808032B1 (he) |
JP (5) | JP5419131B2 (he) |
KR (4) | KR101505201B1 (he) |
AR (1) | AR058326A1 (he) |
AU (1) | AU2006326284B2 (he) |
BR (1) | BRPI0619748B8 (he) |
CA (1) | CA2632822C (he) |
CL (1) | CL2011000010A1 (he) |
CR (3) | CR9995A (he) |
CY (1) | CY1115014T1 (he) |
DK (1) | DK2361638T3 (he) |
EC (1) | ECSP088530A (he) |
ES (1) | ES2454253T3 (he) |
HK (2) | HK1161141A1 (he) |
HR (2) | HRP20140251T1 (he) |
IL (6) | IL191230A (he) |
MA (1) | MA30163B1 (he) |
MX (2) | MX2008007477A (he) |
MY (1) | MY167887A (he) |
NO (1) | NO345996B1 (he) |
NZ (1) | NZ568012A (he) |
PH (1) | PH12011502389A1 (he) |
PL (1) | PL2361638T3 (he) |
PT (1) | PT2361638E (he) |
RS (1) | RS53291B (he) |
RU (2) | RU2015111675A (he) |
SG (1) | SG10201404801YA (he) |
SI (1) | SI2361638T1 (he) |
TW (2) | TWI508975B (he) |
WO (1) | WO2007068412A2 (he) |
ZA (1) | ZA200804916B (he) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
WO2004092197A2 (en) * | 2003-04-07 | 2004-10-28 | The Regents Of The University Of California | Amyloid-specific peptides and uses thereof |
KR101667623B1 (ko) † | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
NO346055B1 (no) | 2005-12-12 | 2022-01-24 | Ac Immune Sa | Antigen konstruksjon, vaksinesammensetning og fremgangsmåte for produksjon derav. |
EP2808032B1 (en) * | 2005-12-12 | 2018-08-01 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US7959949B2 (en) | 2006-04-27 | 2011-06-14 | University Of Central Florida Research Foundation, Inc. | Functionalized nanoceria composition for ophthalmic treatment |
EP3988566A1 (en) * | 2006-07-14 | 2022-04-27 | AC Immune SA | Humanized antibody against amyloid beta |
MX2009000476A (es) * | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
ME01758B (me) * | 2006-07-14 | 2014-09-20 | Genentech Inc | Humanizirano protutijelo protiv amiloida beta |
HUE033466T2 (en) * | 2006-10-02 | 2017-12-28 | Ac Immune Sa | Humanized antibody to beta-amyloid |
US20100183513A1 (en) | 2006-11-24 | 2010-07-22 | Wolfgang Froestl | N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
SG177954A1 (en) | 2007-01-05 | 2012-02-28 | Univ Zuerich | Method of providing disease-specific binding molecules and targets |
IL199534A (he) | 2007-01-05 | 2013-01-31 | Univ Zuerich | נוגדן הומאני מבודד המסוגל לזהות neoepitope בחלבון הקשור למחלה, פולינוקלאוטיד שמקודד לנוגדן, וקטור המכיל את פולינוקליאוטיד, תא מארח המכיל את הפולינוקליאוטיד או הווקטור, תכשיר המכיל את הנוגדן ושיטות ושימושים שקשורים לכל אלו |
JP2010515717A (ja) | 2007-01-11 | 2010-05-13 | フィリップス−ウニベルジテート・マールブルク | アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置 |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
US20090022728A1 (en) * | 2007-03-09 | 2009-01-22 | Rinat Neuroscience Corporation | Methods of treating ophthalmic diseases |
WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
US8323654B2 (en) * | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
US9040045B2 (en) * | 2007-05-14 | 2015-05-26 | Medtronic, Inc. | Methods and device to neutralize soluble toxic agents in the brain |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
PL2170389T3 (pl) * | 2007-06-12 | 2015-03-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US9119391B1 (en) | 2007-07-16 | 2015-09-01 | University Of Central Florida Research Foundation, Inc. | Polymer coated ceria nanoparticles for selective cytoprotection |
AU2008311367B2 (en) * | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
AU2015200604B2 (en) * | 2007-10-05 | 2016-10-27 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
BRPI0818623A2 (pt) * | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal |
EP2205631B1 (en) * | 2007-10-05 | 2016-11-23 | Genentech, Inc. | Methods and compositions for diagnosis and treatment of amyloidosis |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
WO2009104736A1 (ja) * | 2008-02-22 | 2009-08-27 | 財団法人ヒューマンサイエンス振興財団 | 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物 |
US8916199B1 (en) | 2008-04-25 | 2014-12-23 | University of Central Florida Research Foundation, Ind. | Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide |
WO2009132277A1 (en) * | 2008-04-25 | 2009-10-29 | The Board Of Regents Of The University Of Oklahoma | Inhibition of neovascularization by cerium oxide nanoparticles |
AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
JP2011527338A (ja) * | 2008-07-09 | 2011-10-27 | ユニバーシティー オブ チューリッヒ | 神経新生を促進する方法 |
US9127202B1 (en) | 2008-07-18 | 2015-09-08 | University Of Central Florida Research Foundation, Inc. | Biocompatible nano rare earth oxide upconverters for imaging and therapeutics |
CN102131519B (zh) | 2008-07-21 | 2016-01-13 | 前体生物药物股份公司 | 诊断抗体测定 |
EP2149380A1 (en) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction. |
EP2949666B1 (en) | 2008-12-19 | 2018-12-19 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
US8883519B1 (en) | 2009-03-17 | 2014-11-11 | University Of Central Florida Research Foundation, Inc. | Oxidase activity of polymeric coated cerium oxide nanoparticles |
US9585840B1 (en) | 2009-07-10 | 2017-03-07 | University Of Central Florida Research Foundation, Inc. | Redox active cerium oxide nanoparticles and associated methods |
KR101755737B1 (ko) | 2009-09-11 | 2017-07-07 | 프로비오드룩 아게 | 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체 |
US8795731B1 (en) | 2009-10-12 | 2014-08-05 | University Of Central Florida Research Foundation, Inc. | Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation |
EP2311823A1 (en) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
CN102051407B (zh) * | 2009-11-09 | 2012-12-12 | 中国医学科学院医药生物技术研究所 | Hiv-1前体蛋白早成熟化诱导剂的筛选方法 |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
EP2542579A1 (en) | 2010-03-03 | 2013-01-09 | Boehringer Ingelheim International GmbH | Biparatopic abeta binding polypeptides |
CA2789440C (en) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
CN102939282B (zh) | 2010-04-16 | 2015-12-02 | Ac免疫有限公司 | 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物 |
EP2377860A1 (en) | 2010-04-16 | 2011-10-19 | AC Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
CA2806909C (en) | 2010-07-30 | 2019-12-17 | Ac Immune S.A. | Safe and functional humanized antibodies |
WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
US8877207B2 (en) | 2010-09-17 | 2014-11-04 | University Of Central Florida Research Foundation, Inc. | Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods |
CA2813833C (en) | 2010-10-26 | 2020-09-22 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
US20120171120A1 (en) | 2010-11-30 | 2012-07-05 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
US8951539B1 (en) | 2011-06-07 | 2015-02-10 | University Of Central Florida Research Foundation, Inc. | Methods of promoting angiogenesis using cerium oxide nanoparticles |
DK2723379T3 (en) | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
US9161950B2 (en) | 2011-09-21 | 2015-10-20 | University Of Central Florida Foundation, Inc. | Neuronal protection by cerium oxide nanoparticles |
DK2579042T3 (da) * | 2011-10-04 | 2014-07-21 | Affiris Ag | Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve |
WO2013059322A2 (en) * | 2011-10-17 | 2013-04-25 | Lawrence Steinman | Amyloid beta peptide as a therapy for inflammation |
JP6220344B2 (ja) * | 2011-11-29 | 2017-10-25 | プロクララ バイオサイエンシーズ, インコーポレイテッド | アミロイド結合剤としてのバクテリオファージのp3の使用 |
TW201400132A (zh) | 2012-05-21 | 2014-01-01 | Genentech Inc | 改善血腦屏障運送之安全性之方法 |
RU2014153675A (ru) * | 2012-07-03 | 2016-08-27 | Янссен Альцгеймер Иммунотерапи | Антитела к с-концевым и центральным эпитопам а-бета |
WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
CN109846862A (zh) * | 2012-10-25 | 2019-06-07 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
US9463437B2 (en) | 2013-02-14 | 2016-10-11 | University Of Central Florida Research Foundation, Inc. | Methods for scavenging nitric oxide using cerium oxide nanoparticles |
ES2673583T3 (es) * | 2013-02-28 | 2018-06-22 | National Cancer Center | Anticuerpo contra fibrina insoluble |
US9708406B2 (en) | 2013-05-20 | 2017-07-18 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
KR102332302B1 (ko) | 2013-09-13 | 2021-12-01 | 제넨테크, 인크. | 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법 |
CA3184564A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2 |
KR20160111039A (ko) * | 2014-02-08 | 2016-09-23 | 제넨테크, 인크. | 알츠하이머 질환을 치료하는 방법 |
CN107001473B (zh) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
WO2018018031A1 (en) * | 2016-07-22 | 2018-01-25 | New York University | Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides |
US10385096B2 (en) * | 2016-08-30 | 2019-08-20 | Council Of Scientific & Industrial Research | Pro-Amb reverse turn restricted bioactive peptide analogues |
US11397188B2 (en) * | 2017-03-30 | 2022-07-26 | Board Of Regents, The University Of Texas System | Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease |
MA49947B1 (fr) | 2017-08-22 | 2023-03-31 | Biogen Ma Inc | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
EP3801618A4 (en) | 2018-05-30 | 2022-07-27 | National Health Research Institutes | ANTI-ABETA ANTIBODIES AND USES THEREOF |
EP3877399A4 (en) | 2018-11-06 | 2022-10-19 | Alsatech, Inc. | CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES |
EP3946605A1 (en) | 2019-04-05 | 2022-02-09 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
US20230027014A1 (en) * | 2019-11-12 | 2023-01-26 | Ambetex Pty Ltd | Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
CN113057963B (zh) * | 2021-03-31 | 2022-05-20 | 华中科技大学 | 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US5231170A (en) | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US5525339A (en) | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
DE3702789A1 (de) | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
CA1340802C (en) | 1987-08-15 | 1999-10-26 | Yasuyuki Takahashi | Senile amyloid precursor protein and an antibody specific for the same |
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
US6287793B1 (en) | 1988-08-19 | 2001-09-11 | Elan Pharmaceuticals, Inc. | Diagnostic methods for alzheimer's disease |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5262332A (en) | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
US5234814A (en) | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
WO1993010459A1 (en) | 1991-11-12 | 1993-05-27 | The University Of Melbourne | A method for assaying and treating alzheimer's disease |
US5811517A (en) * | 1992-01-27 | 1998-09-22 | Icos Corporation | ICAM-related protein variants |
US20010029293A1 (en) | 1992-01-27 | 2001-10-11 | Icos Corporation | Icam-related protein |
US5538845A (en) | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
US5605811A (en) | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
US5891623A (en) | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
ZA938243B (en) | 1992-11-12 | 1995-05-04 | Hybritech Inc | Altered affinity polypeptides of metal chelate binding antibodies |
US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5750349A (en) | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
AU7949394A (en) * | 1993-11-19 | 1995-06-06 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
CA2127476C (en) | 1994-07-06 | 1999-12-07 | Daniel G. Pomerleau | Logging or measurement while tripping |
US5626332A (en) * | 1994-07-29 | 1997-05-06 | Harris Corporation | Vibration isolation system using plural signals for control |
PT804584E (pt) | 1994-10-21 | 2002-11-29 | Innogenetics Nv | Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
JPH11514333A (ja) | 1995-03-14 | 1999-12-07 | プレーシス ファーマスーティカルズ インコーポレイテッド | アミロイドの凝集の調節剤 |
US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
AU6255096A (en) * | 1995-06-07 | 1996-12-30 | Mount Sinai School Of Medicine Of The City University Of New York, The | Pegylated modified proteins |
JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性appの定量法 |
US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6998124B1 (en) * | 1999-04-14 | 2006-02-14 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
PT1409654E (pt) | 1999-06-16 | 2008-11-25 | Boston Biomedical Res Inst | Controlo imunológico dos níveis de beta-amilóide in vivo |
US6919075B1 (en) * | 1999-09-03 | 2005-07-19 | Ramot At Tel Aviv University Ltd. | Bacteriophage displaying aβ epitopes and method of use |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
DK1481992T3 (en) * | 2000-02-24 | 2017-01-30 | Washington Univ St Louis | Humanized antibodies which sequester amyloid beta peptide |
EP1130032A1 (en) | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) |
US6664442B2 (en) | 2000-03-30 | 2003-12-16 | Elan Pharmaceuticals, Inc. | Selecting compounds to reduce inflammation associated with Alzheimer's disease |
US7371365B2 (en) | 2000-04-04 | 2008-05-13 | Mayo Foundation For Medical Education And Research | Methods for detecting parenchymal plaques in vivo |
US20020009445A1 (en) | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
CA2421374C (en) | 2000-09-06 | 2017-03-07 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US20040191264A1 (en) | 2001-02-19 | 2004-09-30 | Nielsen Klaus Gregorius | Synthetic vaccine agents |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
EP1385544B1 (en) | 2001-04-30 | 2008-09-24 | Eli Lilly And Company | Humanized antibodies |
ES2318006T3 (es) | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
DE50103881D1 (de) | 2001-06-12 | 2004-11-04 | Wiltfang Jens | Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa |
US6638722B2 (en) * | 2001-06-13 | 2003-10-28 | Invitrogen Corporation | Method for rapid amplification of DNA |
US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
CN1396183A (zh) | 2001-07-13 | 2003-02-12 | 张小如 | 降低脑内与老年痴呆有关的淀粉样变纤维的融合人抗体 |
DE60226036T9 (de) | 2001-08-03 | 2016-09-29 | Medical & Biological Laboratories Co., Ltd. | ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT |
US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
AU2002324468A1 (en) | 2001-08-17 | 2003-03-03 | Eli Lilly And Company | Rapid improvement of cognition in conditions related to abeta |
ES2391905T3 (es) | 2001-08-17 | 2012-11-30 | Washington University | Método de ensayo para la enfermedad de alzheimer |
WO2003016467A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
CA2504349A1 (en) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid |
CA2500462A1 (en) | 2001-12-26 | 2004-03-25 | Universidad De Zaragoza | Polyclonal antibodies, preparation method thereof and use of same |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
WO2003089460A1 (en) | 2002-04-19 | 2003-10-30 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
ATE419871T1 (de) | 2002-04-25 | 2009-01-15 | Lilly Co Eli | Verfahren zur behandlung von angststörungen bei älteren personen |
CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
AU2003270643A1 (en) | 2002-09-12 | 2004-04-30 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
US20070213512A1 (en) | 2002-10-01 | 2007-09-13 | Krafft Grant A | Amyloid beta peptide analogs and assemblies thereof |
JP2006519762A (ja) | 2002-10-09 | 2006-08-31 | ライナット ニューロサイエンス コーポレイション | アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法 |
DE10256900A1 (de) * | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
WO2004056318A2 (en) | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
EP1439192A1 (en) * | 2003-01-15 | 2004-07-21 | Xerion Pharmaceuticals AG | Neuropilin-1 inhibitors |
MXPA05006940A (es) | 2002-12-24 | 2006-02-22 | Neurochem Int Ltd | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. |
US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
AU2004209981B2 (en) | 2003-02-01 | 2009-02-26 | Janssen Sciences Ireland Uc | Active immunization to generate antibodies to soluble A-beta |
WO2004071408A2 (en) * | 2003-02-10 | 2004-08-26 | Applied Molecular Evolution, Inc. | Aβ BINDING MOLECULES |
US20040242845A1 (en) | 2003-02-21 | 2004-12-02 | Nicolau Yves Claude | Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them |
EA200501524A1 (ru) | 2003-03-28 | 2006-06-30 | Сентокор, Инк. | Антитела против амилоида, композиции, способы и применения |
EP1469312A1 (en) | 2003-04-18 | 2004-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis of Alzheimer's disease |
US20040223912A1 (en) | 2003-05-07 | 2004-11-11 | Montalto Michael Christopher | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
ES2246177B1 (es) | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
EP1480041A1 (en) | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
US20050124016A1 (en) | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
EP1660533A4 (en) | 2003-09-12 | 2009-10-21 | Univ California | SPECIFIC MONOCLONAL ANTIBODIES MADE FROM PROTEINS OF DIFFERENT SEQUENCES FOR HIGHLY MOLECULAR AGGREGATIVE INTERMEDIATE PRODUCTS OF AMYLOIDS |
US20070015218A1 (en) | 2003-10-14 | 2007-01-18 | University Of South Florida | A Method for the Separation Anti-Amyloid Beta Antibody with Amyloid Beta Peptide |
JP4870348B2 (ja) | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
EP1717250A4 (en) | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | MONOCLONAL ANTIBODY AND ITS USE |
CA2556436C (en) | 2004-02-23 | 2014-04-01 | Eli Lilly And Company | Process for preparing anti-a.beta. antibody |
WO2005105998A1 (ja) * | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
AU2005269940A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta) |
US20090156471A1 (en) | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
AP2007003890A0 (en) | 2004-07-30 | 2007-02-28 | Rinat Neuroscience Corp | Antibodies directed against amy-loid-beta peptide and methods using same |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US20060246075A1 (en) | 2004-09-29 | 2006-11-02 | Marc Mercken | Anti-amyloid antibodies, compositions, methods and uses |
CA2583017A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
EP2465872A3 (en) | 2004-10-25 | 2012-12-19 | Merck Sharp & Dohme Corporation | Anti-ADDL antibodies and uses thereof |
US20060160161A1 (en) | 2004-10-26 | 2006-07-20 | Elan Pharmaceuticals, Inc. | Methods for assessing antibodies to neurodegenerative disease-associated antigens |
JPWO2006046644A1 (ja) | 2004-10-28 | 2008-05-22 | 三光純薬株式会社 | アルツハイマー病の検定方法及び診断試薬 |
WO2006066049A2 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
EP1838349A1 (en) | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
CA2589860A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 a-베타 올리고머의 정제 방법,당해 비확산성 a-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
ES2402650T3 (es) | 2005-06-17 | 2013-05-07 | Janssen Alzheimer Immunotherapy | Métodos de purificación de anticuerpos anti A beta |
JP2007077103A (ja) | 2005-09-16 | 2007-03-29 | Yokohama City Univ | アルツハイマー病の予防又は治療剤 |
KR101667623B1 (ko) * | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
MX2008006957A (es) | 2005-11-30 | 2008-10-20 | Abbott Lab | Metodos para la preparacion de formas recombinantes de proteina beta-amiloide humana y usos de estas proteinas. |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
EP2808032B1 (en) * | 2005-12-12 | 2018-08-01 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US7427342B2 (en) | 2006-06-02 | 2008-09-23 | General Electric Company | Method and apparatus for shifting current distribution in electrodeionization systems |
MX2009000476A (es) * | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
WO2008008463A2 (en) | 2006-07-14 | 2008-01-17 | Trustees Of Columbia University In The City Of New York | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ |
HUE033466T2 (en) | 2006-10-02 | 2017-12-28 | Ac Immune Sa | Humanized antibody to beta-amyloid |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
US20090232801A1 (en) | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
-
2006
- 2006-12-08 EP EP14166211.4A patent/EP2808032B1/en active Active
- 2006-12-08 JP JP2008544834A patent/JP5419131B2/ja active Active
- 2006-12-08 RS RS20140144A patent/RS53291B/en unknown
- 2006-12-08 NZ NZ568012A patent/NZ568012A/en unknown
- 2006-12-08 SI SI200631766T patent/SI2361638T1/sl unknown
- 2006-12-08 KR KR1020087017127A patent/KR101505201B1/ko active IP Right Grant
- 2006-12-08 MX MX2008007477A patent/MX2008007477A/es active IP Right Grant
- 2006-12-08 SG SG10201404801YA patent/SG10201404801YA/en unknown
- 2006-12-08 EP EP10196705.7A patent/EP2361638B1/en active Active
- 2006-12-08 NO NO20082134A patent/NO345996B1/no unknown
- 2006-12-08 RU RU2015111675/10A patent/RU2015111675A/ru not_active Application Discontinuation
- 2006-12-08 ES ES10196705.7T patent/ES2454253T3/es active Active
- 2006-12-08 PL PL10196705T patent/PL2361638T3/pl unknown
- 2006-12-08 EP EP06829456A patent/EP1959996A2/en not_active Withdrawn
- 2006-12-08 CA CA2632822A patent/CA2632822C/en active Active
- 2006-12-08 KR KR1020157021618A patent/KR20150098683A/ko not_active Application Discontinuation
- 2006-12-08 PT PT101967057T patent/PT2361638E/pt unknown
- 2006-12-08 AU AU2006326284A patent/AU2006326284B2/en active Active
- 2006-12-08 WO PCT/EP2006/011862 patent/WO2007068412A2/en active Application Filing
- 2006-12-08 DK DK10196705.7T patent/DK2361638T3/en active
- 2006-12-08 RU RU2008128139/10A patent/RU2551782C2/ru active
- 2006-12-08 MY MYPI20081950A patent/MY167887A/en unknown
- 2006-12-08 BR BRPI0619748A patent/BRPI0619748B8/pt active IP Right Grant
- 2006-12-08 MX MX2012002392A patent/MX358175B/es unknown
- 2006-12-08 KR KR1020147030095A patent/KR101591223B1/ko active IP Right Grant
- 2006-12-08 KR KR1020147004753A patent/KR101591206B1/ko active IP Right Grant
- 2006-12-11 US US11/637,213 patent/US7772375B2/en active Active
- 2006-12-12 AR ARP060105475A patent/AR058326A1/es active IP Right Grant
- 2006-12-12 TW TW095146548A patent/TWI508975B/zh active
- 2006-12-12 TW TW103104624A patent/TWI579303B/zh active
-
2008
- 2008-05-01 IL IL191230A patent/IL191230A/he active IP Right Grant
- 2008-05-20 CR CR9995A patent/CR9995A/es not_active Application Discontinuation
- 2008-06-05 ZA ZA2008/04916A patent/ZA200804916B/en unknown
- 2008-06-12 EC EC2008008530A patent/ECSP088530A/es unknown
- 2008-07-11 MA MA31117A patent/MA30163B1/fr unknown
-
2009
- 2009-10-23 US US12/589,570 patent/US20100297132A1/en not_active Abandoned
-
2010
- 2010-02-05 US US12/701,199 patent/US20110070613A1/en not_active Abandoned
- 2010-02-25 JP JP2010039568A patent/JP2010187674A/ja not_active Withdrawn
-
2011
- 2011-01-05 CL CL2011000010A patent/CL2011000010A1/es unknown
- 2011-11-15 PH PH12011502389A patent/PH12011502389A1/en unknown
-
2012
- 2012-02-29 HK HK12102086.7A patent/HK1161141A1/xx unknown
- 2012-05-01 US US13/461,658 patent/US20120244165A1/en not_active Abandoned
- 2012-07-25 US US13/558,256 patent/US20120288896A1/en not_active Abandoned
- 2012-11-08 IL IL222923A patent/IL222923B/he active IP Right Grant
-
2013
- 2013-10-17 JP JP2013216451A patent/JP2014039561A/ja not_active Withdrawn
-
2014
- 2014-03-18 HR HRP20140251TT patent/HRP20140251T1/hr unknown
- 2014-04-04 CY CY20141100259T patent/CY1115014T1/el unknown
- 2014-04-07 HR HRP20140333TT patent/HRP20140333T1/hr unknown
- 2014-08-21 CR CR20140394A patent/CR20140394A/es unknown
-
2015
- 2015-01-19 CR CR20150016A patent/CR20150016A/es unknown
- 2015-02-10 IL IL237169A patent/IL237169A0/he unknown
- 2015-02-10 IL IL237167A patent/IL237167A0/he unknown
- 2015-02-10 IL IL237166A patent/IL237166A0/he unknown
- 2015-02-10 IL IL237168A patent/IL237168A0/he unknown
- 2015-06-02 HK HK15105249.1A patent/HK1204579A1/xx unknown
-
2016
- 2016-01-14 JP JP2016004910A patent/JP6174727B2/ja active Active
-
2017
- 2017-03-31 JP JP2017069675A patent/JP2017153480A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1204579A1 (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties a1-42 | |
HRP20181616T1 (hr) | Potpuno ljudska anti-vap-1 monoklonska antitijela | |
IL206710A0 (en) | Il-31 monoclonal antibodies | |
IL196478A0 (en) | Humanized antibody against amyloid beta | |
PL2074145T3 (pl) | Humanizowane przeciwciało przeciw amyloidowi beta | |
ZA201000049B (en) | Monoclonal antibeta amyloid antibody | |
HK1108132A1 (en) | Anti a beta antibody formulation | |
EP1853313A4 (en) | HUMANIZED L243 ANTIBODIES | |
HK1109585A1 (en) | Humanized amyloid beta antibodies for use in improving cognition | |
ZA200904022B (en) | Monoclonal antibodies against ANGPTL3 | |
EP2021373A4 (en) | MONOCLONAL ANTIBODY VCAM-1 SPECIFIC | |
IL200168A0 (en) | Monoclonal anti-cxcl13 antibodies | |
IL254065B (he) | נוגדן אנושי נגד אמילואיד בתא | |
EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
EP1712564A4 (en) | MONOCLONAL ANTIBODY ANTI-NC1 | |
ZA200900313B (en) | Humanized antibody against amyloid beta | |
GB0415644D0 (en) | Monoclonal antibody | |
GB0505054D0 (en) | Antibodies |